From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Response
Daratumumab 16 mg/kg (n = 32)
No.
%
95% CI
ORR
8
25.0
11.5–43.4
Clinical benefit rate (CR + PR + stable disease)
14
43.8
26.4–62.3
CR
0
PR
Stable disease
6
18.8
PD
NE
4
12.5